Clinical Trials · NCT00460811

Randomized, Double-blind, Dose-range-finding, Phase 2 Study of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

Name: Randomized, Double-blind, Dose-range-finding, Phase 2 Study of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 2Linaclotide

Phase: Phase 2
Recruitment status: Completed
Sponsor: Ironwood Pharmaceuticals, Inc.
Enrollment: 420
Start date: Apr 2007
Locations: 85 sites, United States, Canada
Primary endpoint: Change From Baseline in the Weekly Normalized Complete Spontaneous Bowel Movement (CSBM) Rate During Weeks 1 Through 12 of the Treatment Period

View Linaclotide compound reference